文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

迷走神经介导的神经免疫调节治疗类风湿关节炎:一项关键性随机对照试验

Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial.
PubMed 文献 · Nat Med · 2025-12-22

RESET-RA是一项双盲、随机、假刺激对照的关键性试验,纳入242例对生物制剂或靶向合成改善病情抗风湿药应答不足或不耐受的类风湿关节炎患者。患者随机接受活性或假刺激3个月,随后全部接受开放标签刺激至12个月。3个月时活性组ACR20应答率高于假刺激组(35.2% vs 24.2%,P=0.0209),开放标签阶段6个月和12个月分别升至50.0%和52.8%(完成者分析)。不良事件两组比例相似,相关严重不良事件发生率1.6%,均为围手术期事件且已缓解。

要点

  • 3个月时活性刺激组ACR20应答率35.2%,假刺激组24.2%(P=0.0209)。
  • 开放标签阶段6个月和12个月ACR20应答率分别为50.0%和52.8%(完成者分析)。
  • 相关严重不良事件发生率1.6%,均为围手术期事件且已缓解。

核心结论

  • 迷走神经介导的神经免疫调节治疗类风湿关节炎达到了主要疗效终点,并产生持久临床获益且安全性良好。

研究设计与样本

  • RESET-RA为关键性、双盲、随机、假刺激对照试验,纳入242例对生物制剂或靶向合成改善病情抗风湿药应答不足或不耐受的类风湿关节炎患者。
  • 患者随机接受活性或假刺激3个月,随后全部接受开放标签刺激,结果报告至12个月。
  • 主要终点为3个月时美国风湿病学会20%缓解标准(ACR20)应答率。

主要发现

  • 3个月时活性刺激组ACR20应答率为35.2%,假刺激组为24.2%(P=0.0209)。
  • 开放标签阶段6个月时ACR20应答率为50.0%,12个月时为52.8%(完成者分析)。
  • 不良事件发生率两组相似;相关严重不良事件发生率1.6%,均为围手术期事件且已缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The inflammatory reflex, in which vagus nerve signaling modulates cytokine production, is dysregulated in rheumatoid arthritis (RA). RESET-RA, a pivotal, double-blind, randomized, sham-controlled trial, evaluated a vagus nerve-targeted neuromodulation system for RA in 242 patients with inadequate response/intolerance to biological/targeted synthetic disease-modifying antirheumatic drugs. Patients were randomized to active or sham stimulation for 3 months, and then all received open-label stimulation with results reported to 12 months. The primary end point was 3-month American College of Rheumatology 20% (ACR20) response. ACR20 rates were higher with active simulation than with sham at 3 months (35.2% versus 24.2%, P = 0.0209), which further improved in open-label to 50.0% at 6 months and 52.8% at 12 months (all-completers). Adverse events occurred in a similar proportion of patients in both arms. Related serious adverse events (rate = 1.6%) were all perioperative, and resolved. Vagus nerve-mediated neuroimmune modulation for RA achieved its primary efficacy end point and produced durable clinical benefits with a favorable safety profile. ClinicalTrials.gov registration: NCT04539964 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Tesser JRP, Crowley AR, Box EJ, et al. Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. Nat Med. 2025. PMID: 41429981. doi:10.1038/s41591-025-04114-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。